North America is expected to lead the market throughout 2022 and is projected to grow at a CAGR of 11.89%, during 2016 and 2022

08/feb/2021 12:17:12 Automotive Market Research Reports Contatta l'autore

Liver disease is characterized by improper functioning of liver, causing disorders like hepatitis, fatty liver, and cirrhosis. Some of the major drug categories used in the treatment of various types of liver diseases includes antirejecting drugs, vaccines, immunosuppressant, chemotherapy drugs and antiviral drugs.

Liver Disease Treatment Market Report, published by Allied Market Research, forecasts that the global market is expected to garner $19,536 million by 2022, registering a CAGR of 11.72% during the period 2016 – 2022

Key findings of the study: 

  • Corticosteroids drug is projected to be the fastest growing segment, registering a CAGR of 16.49% during the forecast period
  • North America is expected to lead the market throughout 2022 and is projected to grow at a CAGR of 11.89%, during 2016 and 2022
  • Asia-Pacific is expected to grow with a CAGR of around 12.51%, due to increasing prevalence of liver diseases and increasing R&D investments in this region.

North America and Europe collectively accounted for more than two-fourth of the total liver disease treatment market in 2015, and are expected to maintain their position throughout the forecast period. This is due to the increasing prevalence of liver diseases, growing geriatric population, and increased awareness about the various liver diseases and their treatment in these regions. In addition, advancement in R&D is anticipated in the development of novel drug therapy for the treatment of liver diseases.

The prompt players in the liver disease treatment market have adopted strategies such as innovative product launch, merger & acquisition, partnership and business expansion to gain maximum market share. The major companies profiled in the report include, Gilead Science Inc., Bayer AG, AstraZeneca PLC, GlaxoSmithKline plc, Merck & Co. Inc, Sanofi AG , Pfizer Inc., Bristol-Myers Squibb Company, Novartis AG, and Johnson & Johnson Private Limited.

Growing geriatric population

Structural dysfunction or alteration due to aging mainly leads to liver diseases. According to the National Institute of Aging, geriatric population is likely to increase by 86% till 2050. 


Follow Us on LinkedIn:

blog comments powered by Disqus è un servizio offerto da Factotum Srl